Latest News

Energy headwinds and a sweeping restructuring shaped this quarter's results.

Strategic review extended as Témiscaming idles and cash flow turns positive.

Record acquisitions and a credit upgrade shaped the quarter.

Ashland's fiscal 2027 outlook signals a shift toward execution and innovation.

Branded traffic drove growth as Middle East pressures weighed on one region.

Share gains and procurement savings helped PFG navigate a tough consumer backdrop.

Record sales and a raised outlook, but margins slipped on large infrastructure deals.

Fiscal 2027 volume pressure looms as Adient prepares for a CFO handover.

Emerging markets surged while organic sales slipped and margins took a hit.

Management flagged soft Europe and China demand even as 2027 guidance points higher.

Cost cuts lifted margins, but a segment write-down clouded the quarter.

Management reaffirmed its fiscal 2027 outlook as workforce savings ramp up.

Management raised full-year guidance again as double-digit growth continued for a 14th quarter.

Record margins and a pulled-forward NCR Atleos closing date headline the quarter.

Operating income hit a record as advanced packaging demand pushed orders into 2027.

Pharma clients resume R&D spending as organic growth returns.

Global comps rose 1.5% as U.S. value tests gained traction.

Driver shortages in key emerging markets weighed on mobility results this quarter.

WAVE Life Sciences (NASDAQ:WVE) used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing updates on its RNA interference, extrahepatic delivery and bifunctional oligonucl

Reynolds Consumer Products (NASDAQ:REYN) reported third-quarter revenue growth as pricing actions offset lower retail volumes tied to commodity-driven price increases and a pressured consumer environment. The company maintained its full-year outlook while highlighting continued investment in brands,

SolarEdge Technologies (NASDAQ:SEDG) reported third-quarter results that met the midpoint of its revenue and gross-margin guidance, while outlining a lower fourth-quarter outlook amid soft residential solar demand in the United States and policy uncertainty in Germany. Chief Executive Officer Shuki

uniQure (NASDAQ:QURE) said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington’s disease, and granted the application Priority Review with a target action date of May 1, 2027. The U.K. Medicines and Healthcare products Regulatory Agency has

CPI Card Group (NASDAQ:PMTS) reported third-quarter revenue of $158 million, up 15% from the prior-year period and representing the highest quarterly revenue in the company’s history, executives said on its earnings call. Growth was supported by double-digit increases across Secure Card Solutions, P

Insulet (NASDAQ:PODD) reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company’s plans and U.S. performance landed within its guidance range. President and Chief Executive Officer Ashley McEvoy

Ocugen (NASDAQ:OCGN) said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European presence to support future commercialization efforts. Chairman, Chief Executive Officer and Co-Founde